Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Steven M. Devine(National Marrow Donor Program), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alexander B. Sibley(Duke University), Ravi Vij(Washington University in St. Louis), Kouros Owzar(Duke University), Yi‐Bin Chen(Massachusetts General Hospital), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Flora Mulkey(Sherwin Williams (United States)), Shelly Carter(European Society for Blood and Marrow Transplantation), Robert J. Soiffer(Dana-Farber Cancer Institute), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Richard M. Stone(Dana-Farber Cancer Institute), Richard A. Larson(Urbana University), Mary M. Horowitz(Medical College of Wisconsin), Thomas C. Shea(University of North Carolina at Chapel Hill), Charles Linker(University of California, San Francisco), James L. Slack(Memorial Sloan Kettering Cancer Center), William Blum(The Ohio State University), Jack W. Hsu(University of Florida Health), Vera Hárs
Cited by 163
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k